Lv7
4538 积分 2022-08-01 加入
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
8小时前
已关闭
PD-1免疫抑制剂联合放疗治疗驱动基因阴性非小细胞肺癌的研究进展
15天前
已完结
[Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer]
1个月前
已完结
Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase 1b/2 dose-escalation and dose-expansion study
1个月前
已完结
The next generation of immunotherapies for lung cancers
1个月前
已完结
Bioanalytical assay strategies for the development of antibody–drug conjugate biotherapeutics
1个月前
已完结
Dual-payload ADCs move into first oncology clinical trials
1个月前
已完结
Treatment of small cell lung cancer; advances and future prospects
1个月前
已完结
Current Trends in the Management of Recurrent Nasopharyngeal Carcinoma
1个月前
已完结
Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges
2个月前
已完结
皖公网安备34019202002308
